Abstract
Transplantation of solid organs has been well established as a mode of therapy for the treatment of various end-stage organ diseases for many years. Up to now, it has benefited more than 1 million patients worldwide. The long- term success of organ transplantation depends particularly on the prevention of allograft rejection. Various regimens have been used to suppress hosts’ cellular immune responsiveness to the grafted organs. Nowadays immunosuppressive therapies consist mainly in prednisolone, azathioprine, cyclosporine, anti-T-lymphocyte-globulin (ATG), anti-CD 3 antibody (OKT3) and substances of a new generation, such as tacrolimus or mycophenolic acid. However, not only the patient’s reactivity to the graft is impaired, but also that to infectious organisms. Chronically altered immune responsiveness is especially associated with a dramatically increased risk of malignancy, most frequently non-Hodgkin’s lymphoma and skin cancer. Within the first 5 years of immunosuppression 40% of transplant recipients experience premalignant skin tumors such as actinic keratoses and Bowen’s disease, and also such skin cancers as squamous cell carcinomas and basal cell carcinomas. Quite often these have an aggressive biology and an uncommon morphology. Cancer is now responsible for a mortality rate of 5–8% in organ transplant patients.
Various risk factors, such as exposure to sun and infections with oncogenic viruses (e.g. HPV) contribute to the already increased risk of dysplasia when lifelong immunosuppression is required. Prophylactic strategies therefore include the development of virus-like particles (VLPs) as anticancer vaccines, which might become a very interesting approach to preventing HPV- associated cancer. The prevention of precancerous conditions and mature skin cancers in grafted patients includes protective clothing and adequate protection of UV-exposed skin regions, including lips, from sunlight with appropriate sunscreen. Close dermatological surveillance through a specialized outpatient department should be ensured to detect potentially fatal skin malignancies at an early stage. Early treatment of precancerous lesions includes topical retinoids, such as tretionin, tazarotene or adapalene. A 5% fluorouracil cream is widely used but shows variable effects on manifest actinic keratoses. As cellular immunity seems to play the major part in the prevention and cure of malignant and premalignant cutaneous neoplasias as well as viral infections, a specific enhancement of agents known as immune response modifiers. The drug has been shown to have both antiviral and antitumor activity. Applications of immune response activators or modifiers such as imiquimod might be premising in the case of transplant recipients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177–186.
Bouwes Bavinck JN, Hardie DR, Green A, et al. (1996) The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 61:715–721.
Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, Vandenbroucke JP, Geziena M, Schreuder GMT, et al. (1991) Relation between skin cancer and HLA antigens in renal- transplant recipients. N Engl J Med 325:843–848.
Espana A, Redondo P, Fernandez AL, Zambala M, Herreros J, Llorens R, Quintanilla E (1995) Skin cancer in heart transplant recipients. J Am Acad Dermatol 32:458–465.
Boyle J, Mackie RM, Briggs JD, Junor BJR, Aitchison TC (1984) Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1:702–704.
Leigh IM, Buchanan JA, Harwood CA, Cerio R, Storey A (1999) Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. J Acquir Immune Defic Syndr 21:S49–S57.
Gupta AK, Cardella CJ, Habermann HF (1986) Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 122:1288–1293.
Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ (1980) Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 87:177–183.
Penn I, Brunson ME (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274–278.
Leveque L, Dalac S, Dompmartin A, Louvet S, Euvrard S, et al. (2000) Melanoma in organ transplant patients. Ann Dermatol Venerol 127:160–165.
Penn I, Brunson ME (1988) Cancers after cyclosporine therapy. Transplant Proc 20:885–892.
Penn I (1998) Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant 1998:147–158.
O’Connell BM, Abel EA, Nickoloff BJ, et al. (1986) Dermatologic complications following heart transplantation. J Heart Lung Transplant 5:430–436.
Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534.
Stockfleth E, Ulrich C, Meyer T, Arndt R, Christophers E (2001) Skin diseases following organ transplantation-risk factors and new therapeutic approaches. Transplant Proc 33:1848–1853.
Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM (1999) Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 40:27–34.
Majewski S, Jablonska S (1995) Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 131:1312–1318.
Orth G, Jablonska S, Jarzabek-Chorzelsk M, et al. (1979) Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res 39:1074–1082.
Orth G (1987) Epidermodysplasia verruciformis. In: Salzman NP, Howley PM (eds) The Papovaviridae, the papillomaviruses. Plenum, New York, pp 199–235.
Blessing K, McLaren LM, Benton EC, et al. (1989) Histopathology of skin lesions in renal allograft recipients: an assessment of viral features and dysplasia. Histopathology 14:129–139.
Pfister H, ter Schegget J (1997) Role of HPV in cutaneous premalignant and malignant tumors. Clin Dermatol 15:335–348.
Berkhout RJ, Tieben LM, Smits HL, et al. (1995) Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 33:690–695.
Meyer T, Arndt R, Christophers E, et al. (2000) Frequency and spectrum of HPV types detected in cutaneous squamous cell carcinomas depend on the HPV detection system: a comparison of four PCR assays. Dermatology 201:204–211.
De Villiers EM, Lavergne D, McLaren K, et al. (1997) Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 73:356–361.
Jackson S, Storey A (2000) E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 27:592–598.
Purdie KJ, Pennington J, Proby CM, et al. (1999) The promotor of a novel human papillomavirus (HPV 77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J 18:5359–5369.
Astori G, Lavergne D, Benton C, et al. (1998) Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 110:752–755.
Boxman ILA, Berkhout RJM, Mulder LHC, et al. (1997) Detection of human papilloma-virus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 108:712–715.
Bens G, Wieland U, Hofmann A, Hopfl R, Pfister H (1998) Detection of a new human papillomavirus sequence in skin lesions of a renal transplant recipient and characterization of the complete genome related to epidermodysplasia verruciformis associated types. J Gen Virol 79:779–787.
Edwards L, Levine N, Weidner M, Piepkorn M, Smiles K (1986) Effect of intralesional alpha 2-interferon on actinic keratoses. Arch Dermatol 122:779–782.
Aranay I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB (1999) Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 43:55–63.
Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB (1998) A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with Imiquimod. J Infect Dis 178:551–555.
Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth E, Goos M (2000) Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 143:1026–1031.
Stockfleth E, Meyer T, Benninghoff B, et al. (2001) Successful treatment of actinic keratosis with imiquimod cream 5%: a report of 6 cases. Br J Dermatol 144:1050–1053.
Schiller JT (1999) Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 5:209–215.
Miiller M, Zhou J, Reed TD, Rittmiiller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L (1997) Chimeric papillomavirus-like particles. Virology 234:93–111.
Schäfer K, Miiller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I (1999) Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T-cells and specific tumor protection. Int J Cancer 81:881–888.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stockfleth, E., Ulrich, C., Meyer, T., Christophers, E. (2002). Epithelial Malignancies in Organ Transplant Patients: Clinical Presentation and New Methods of Treatment. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-59410-6_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63969-2
Online ISBN: 978-3-642-59410-6
eBook Packages: Springer Book Archive